RUA Life Sciences (RUA) AI Stock Analysis

• Market Cap: £8.07M
• Dividend Yield: N/A
• Average Volume (3M): 148.53K
• Price to Earnings (P/E): 3.6
• Beta (1Y): 0.22
• Revenue Growth: 87.72%
• EPS Growth: N/A
• Country: UK
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): <0.01
• Shares Outstanding: 62,060,272
• 10 Day Avg. Volume: 90,619
• 30 Day Avg. Volume: 148,527
• PEG Ratio: -75.00
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 1.82
• P/FCF Ratio: -26.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): £6.78M

• Rating: 59 Neutral
• Price Target: 13.50 p ▼(-3.57% Downside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

The score is primarily driven by solid top-line growth and a conservative balance sheet, but it is held back by weak profitability and negative operating cash flow. Technicals are supportive due to an established uptrend, yet the very high P/E meaningfully detracts from the overall rating.

Positive Factors

High revenue growth & gross margin

Sustained 40.8% revenue growth alongside a 77% gross margin indicates durable product demand and favourable unit economics in biomaterials. Over 2-6 months this supports reinvestment in R&D and commercialization, enabling scale without immediate margin erosion and improving long-term competitiveness.

Conservative balance sheet / low leverage

A low debt-to-equity ratio provides financial flexibility to fund clinical development, regulatory steps, or capacity expansion without heavy interest burdens. This conservative capital structure reduces refinancing risk and supports strategic decisions across the medical device product cycle over the medium term.

Specialized biomaterials and diversified activities

A focused, integrated business model—covering biomaterials production and device-related activities—creates barriers to entry and cross-selling opportunities. Ownership of both materials and device support services can deepen customer relationships and secure recurring demand from implantable and clinical manufacturers over time.

Negative Factors

Negative operating cash flow

Ongoing negative operating cash flow and falling free cash flow growth strain internal funding for R&D, regulatory submissions, and commercialization. Over a multi-month horizon this increases reliance on external financing, which can dilute shareholders or raise financing costs and constrain strategic investments.

Weak profitability and negative EBIT

Very low net margin and negative EBIT show the company is not yet converting sales into sustainable operating profits. This structural profitability weakness threatens long-term return generation and makes it harder to fund growth internally, requiring margin improvement or cost discipline to achieve durable value creation.

Small workforce may limit scale

A small employee base limits capacity for manufacturing scale-up, regulatory work, and broad commercial rollouts common in med-tech. Over the coming months this can create execution bottlenecks, increase dependency on third parties, and slow time-to-market for new products, hindering durable expansion.

RUA Life Sciences Business Overview & Revenue Model

Company Description

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.

How the Company Makes Money

null

RUA Life Sciences Financial Statement Overview

Summary

Strong revenue growth (40.81%) and a high gross margin (77.12%) support the score, and leverage is low (debt-to-equity 0.14). However, profitability is very weak (near-zero net margin and negative EBIT margin) and cash flow is pressured by negative operating cash flow and declining free cash flow growth.

Income Statement

RUA Life Sciences has shown a strong revenue growth rate of 40.81% in the latest year, indicating a positive trajectory in sales. The gross profit margin remains robust at 77.12%, reflecting efficient cost management. However, the company struggles with profitability, as evidenced by a negligible net profit margin of 0.02% and negative EBIT margin, suggesting operational challenges.

Balance Sheet

The company's balance sheet is relatively stable with a low debt-to-equity ratio of 0.14, indicating conservative leverage. The equity ratio is strong, suggesting a solid capital structure. However, the return on equity is negative in previous years, highlighting challenges in generating returns for shareholders.

Cash Flow

RUA Life Sciences faces cash flow challenges, with negative operating cash flow and a significant decline in free cash flow growth. The free cash flow to net income ratio is positive, indicating some efficiency in converting income to cash, but overall cash flow management remains a concern.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	4.46M	4.11M	2.19M	2.18M	1.63M	1.53M
Gross Profit	3.30M	3.17M	1.72M	1.43M	1.04M	980.00K
EBITDA	272.00K	401.00K	-1.57M	-1.95M	-2.04M	-1.28M
Net Income	-150.34K	1.00K	-1.44M	-2.00M	-2.07M	-1.45M
Balance Sheet
Total Assets	9.12M	9.26M	8.17M	5.66M	7.63M	10.15M
Cash, Cash Equivalents and Short-Term Investments	3.25M	3.57M	3.93M	1.48M	2.96M	6.29M
Total Debt	1.35M	1.03M	389.00K	475.00K	344.00K	410.00K
Total Liabilities	1.93M	1.86M	987.00K	980.00K	1.04M	1.65M
Stockholders Equity	7.14M	7.30M	7.18M	4.68M	6.58M	8.51M
Cash Flow
Free Cash Flow	-323.00K	-281.00K	-1.38M	-1.62M	-3.27M	-2.04M
Operating Cash Flow	-162.00K	-219.00K	-1.33M	-1.17M	-2.36M	-1.42M
Investing Cash Flow	-59.00K	70.00K	-85.00K	-449.00K	-904.00K	-943.00K
Financing Cash Flow	-459.00K	-196.00K	3.89M	132.00K	-66.00K	6.68M

RUA Life Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Negative. The current price of 14 is above the 20-day moving average (MA) of 13.48, above the 50-day MA of 13.98, and above the 200-day MA of 12.44, indicating a neutral trend. The MACD of -0.24 indicates Positive momentum. The RSI at 31.86 is Neutral, neither overbought nor oversold. The STOCH value of 37.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:RUA.

RUA Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RUA	59 Neutral	£8.07M	3.60	0.08%	―	87.72%	―
IHC	52 Neutral	£21.88M	-18.39	-69.35%	―	31.78%	10.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CREO	48 Neutral	£55.17M	0.83	32.72%	―	―	―
GDR	47 Neutral	£16.86M	-1.51	-153.92%	―	90.42%	79.21%
OPTI	43 Neutral	£6.09M	-2.61	-2.42%	―	―	―
SUN	43 Neutral	£4.20M	77.73	-16.78%	―	-4.98%	-114.29%

RUA Life Sciences Corporate Events

RUA Life Sciences Secures Strong Shareholder Backing at AGM

RUA Life Sciences announced that all resolutions proposed at its latest Annual General Meeting were duly passed by shareholders with strong majorities. The voting outcomes, which showed high levels of support and minimal opposition across all 14 resolutions, reaffirm the existing governance structure and strategic direction of the company.

The successful AGM votes provide management with a clear mandate to continue executing its business plan in implantable medical devices and polymer technologies. This outcome signals shareholder confidence in the board and leadership team, supporting stability for ongoing operations and future development initiatives within its specialist healthcare niche.

The most recent analyst rating on (GB:RUA) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on RUA Life Sciences stock, see the GB:RUA Stock Forecast page.

RUA Life Sciences flags growth inflection as CDMO pipeline builds and heart valve deal nears

RUA Life Sciences reported that activity in its UK contract development and manufacturing arm remains strong, with two main manufacturing contracts underpinning revenue and a growing pipeline of development work worth about £500,000 expected to be billed this financial year. Around 60% of these projects relate to approved or near-approved products, giving the company line of sight to potential manufacturing contracts exceeding £5 million annually and supporting management’s view that the business has reached a key growth inflection point.

The Abiss unit is currently trading below budget as a major customer runs down inventories, and RUA is negotiating an arrangement to align stock levels while securing two-year revenue visibility. Meanwhile, the biomaterials division is trading broadly in line with prior periods with further growth expected from a new Elast-Eon contract and potential royalty uplift, and the structural heart unit has signed Heads of Terms for third-party funding to advance pre-clinical development of a novel AurTex-based heart valve, reinforcing the value of the Group’s IP and partnerships.

The most recent analyst rating on (GB:RUA) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on RUA Life Sciences stock, see the GB:RUA Stock Forecast page.

RUA Life Sciences Posts Annual Report and Sets March AGM Date

RUA Life Sciences has distributed its Annual Report and Accounts together with the notice of its upcoming Annual General Meeting to shareholders, and made these documents available on its investor relations website. The AGM is scheduled to take place on 17 March 2026 at the Gailes Hotel in Irvine, Ayrshire, giving investors an opportunity to review performance, governance matters and engage with the company’s leadership on its strategic direction.

The publication of the annual report and the convening of the AGM mark a key point in the company’s corporate calendar, underscoring ongoing transparency and regulatory compliance for its AIM listing. Shareholders now have formal access to detailed financial and operational disclosures, which may shape sentiment toward RUA Life Sciences’ progress in commercialising its implantable polymer technology and its broader position in the medical device sector.

The most recent analyst rating on (GB:RUA) stock is a Hold with a £14.00 price target. To see the full list of analyst forecasts on RUA Life Sciences stock, see the GB:RUA Stock Forecast page.

RUA Life Sciences Triples Revenues and Nears Profitability After Abiss Acquisition

RUA Life Sciences has delivered a transformational 18‑month period to 30 September 2025, more than tripling revenue to £6.7m compared with the prior 12‑month period, while sharply reducing its loss before tax to £0.2m and turning EBITDA positive at £0.4m. The purchase of French CDMO Abiss has strengthened its contract manufacturing platform, contributed a £0.9m bargain‑purchase gain and helped lift CDMO revenues to £5.8m, while biomaterials income grew 23% on a like‑for‑like basis to £914,000 despite currency headwinds; combined with cost-cutting, reduced R&D spend and a refocus from R&D-heavy development to commercially driven growth, the group has achieved its 2023 strategic goals of doubling revenue, lowering cash burn and moving toward sustainable profitability ahead of schedule. With year‑end cash of £3.25m, improving cash generation from operations and an expanding pipeline of development and manufacturing contracts, management expects current activity levels to continue, positioning the company to broaden services to existing clients, win new customers and further commercialise its vascular and structural heart intellectual property in a highly regulated, long‑cycle but high‑margin medical device market.

The most recent analyst rating on (GB:RUA) stock is a Hold with a £16.00 price target. To see the full list of analyst forecasts on RUA Life Sciences stock, see the GB:RUA Stock Forecast page.